This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Why the Data Didn't Matter

But Cramer said he's not buying those rumors since bringing a new drug to market involves a ton of paperwork that takes at least six to 12 months to complete. So far, no paperwork for a would-be Acthar competitor has surfaced.

He said that Novartis (NVS) does sell a similar drug in Europe, but the economics don't work for the company to bring the drug to the U.S. since Questcor's 19 indications would involve 19 clinical trials to be performed before that drug would be on the same playing field as Acthar.

Cramer said these rumors of "questionable" origin are at odds with the Questcor, which just received orphan drug status for Acthar, giving it even more incentives for making the drug. The company also just reported terrific prescription data, which shows how much doctors love the drug.

So in the battle that has become Questcor, Cramer said he's siding with the bulls as this stock is not yet done going higher.

Lightning Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

Nvidia (NVDA): "People are worried about the quarter. I say don't buy." (BIDU): "I am not recommending any Chinese stocks right now."

WW Grainger (GWW): "Any weakness, I want to buy this one. It's a terrific company."

Nordic American Tanker (NAT): "The daily tanker rates are horrendous. I think you need to sit on the sidelines for now."

Bank of America (BAC): "Bank of America is good to go. I think you can own it. "

Consolidated Edison (ED): "I do like their dividend. I'd use $58 as my entry point."

Executive Decision

In the "Executive Decision" segment, Cramer sat down with David Pyott, chairman, president and CEO of Allergan (AGN), which remains the fastest-growing medical company out there as it continues to find new uses for older products.

Pyott said the consumer is "alive and well," something that has helped Allergan continue to grow at a rate of 9.5% a year when adjusting for currencies. He also noted that the second half of 2012 is poised to be even better than the first, thanks to a competitor for Botox being taken off the market.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs